News & Media

Recent updates from Arcutis.

July 9, 2024 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

December 15, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

October 6, 2023 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

March 7, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

March 5, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2025

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

February 26, 2025

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

February 25, 2025

Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 24, 2025

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

February 18, 2025

Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

February 5, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 4, 2025

Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a “Clear Win for Your Skin”

January 27, 2025

Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

January 12, 2025

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

January 6, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download